Title :

Mixed connective tissue disease: state of the art on clinical practice guidelines.

Author(s) :

Chaigne, Benjamin [Auteur]
Scire, Carlo Alberto [Auteur]
Talarico, Rosaria [Auteur]
Alexander, Tobias [Auteur]
Amoura, Zahir [Auteur]
Avcin, Tadej [Auteur]
Beretta, Lorenzo [Auteur]
Doria, Andrea [Auteur]
Guffroy, Aurelien [Auteur]
Guimaraes, Vera [Auteur]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Krieg, Thomas [Auteur]
Launay, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lepri, Gemma [Auteur]
Moinzadeh, Pia [Auteur]
Mueller-Ladner, Ulf [Auteur]
Rednic, Simona [Auteur]
Rodrigues, Ana [Auteur]
Tas, Sander W [Auteur]
Van Vollenhoven, Ronald F. [Auteur]
Vieira, Ana [Auteur]
Bombardieri, Stefano [Auteur]
Fonseca, Joao Eurico [Auteur]
Galetti, Ilaria [Auteur]
Schneider, Matthias [Auteur]
Smith, Vanessa [Auteur]
Cutolo, Maurizio [Auteur]
Mosca, Marta [Auteur]
Fischer-Betz, Rebecca [Auteur]

Journal title :

RMD open

Abbreviated title :

RMD Open

Volume number :

4

Pages :

e000783

Publication date :

2018-01-01

ISSN :

2056-5933

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematous ...
Show more >Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematous in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle. In this narrative review, we summarise the results of a systematic literature research which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines (CPGs) or recommendations. Since no specific CPGs on MCTD were found, other CPGs developed for other CTDs were taken into consideration in order to discuss what can be applied to MCTD even if designed for other diseases. Three major objectives were proposed for the future development of CPGs: MCTD diagnosis (diagnostic criteria), MCTD initial and follow-up evaluations, MCTD treatment. Early diagnosis, epidemiological data, assessment of burden of disease and QOL aspects are among the unmet needs identified by patients.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2019-10-22T07:44:44Z